Bharat Parenterals Peer Comparison

Snapshot Summary

Bharat Parenterals Ltd. exhibits promising growth metrics but struggles with profitability compared to its peers, which are predominantly more established. Companies like Cipla and Dr. Reddy's lead in profitability, while Bharat Parenterals may represent a growth opportunity at a reasonable valuation despite its current financial challenges.

• Bharat Parenterals shows significant revenue growth but has negative EPS, indicating potential for improvement.
• Cipla and Dr. Reddy's have superior profitability metrics and low valuation ratios, making them attractive investments.
• Bharat Parenterals' debt levels are manageable, suggesting financial stability compared to more leveraged peers.

• Cipla Ltd.: Strong profitability with a low PE ratio and high ROE.
• Dr. Reddy's Laboratories Ltd.: Excellent profitability metrics with low valuation ratios.
• Mankind Pharma Ltd.: High growth metrics and strong financial ratios.

Stock	CMP	Market Cap	P/E	ROE (%)	ROCE (%)	Debt/Equity
Bharat Parenterals Ltd.	₹1,183.15	₹815.42Cr	-143.81	-16.55%	-4.85%	0.55
SUNPHARMA	₹1,706.40	₹4,09,626.46Cr	39.49	16.16%	19.89%	0.03
DIVISLAB	₹6,804.00	₹1,80,668.62Cr	78.35	15.35%	20.45%	0.00
CIPLA	₹1,511.50	₹1,22,102.70Cr	22.44	16.63%	22.77%	0.01
TORNTPHARM	₹3,628.30	₹1,20,456.12Cr	60.17	26.46%	27.32%	0.40
DRREDDY	₹1,196.00	₹99,965.86Cr	17.32	18.61%	23.25%	0.14
ZYDUSLIFE	₹981.05	₹98,057.50Cr	21.45	21.08%	26.06%	0.13

Explore

Watchlists

Command Palette

Bharat Parenterals Peer Comparison

Snapshot Summary